Should I buy or sell Entrada Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks .

What is Entrada Therapeutics' stock price target for 2024?

2 analysts have issued 12 month price targets for Entrada Therapeutics' stock. Their TRDA share price targets range from $20.00 to $22.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 72.8% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts .

How have TRDA shares performed in 2024?

Entrada Therapeutics' stock was trading at $15.09 on January 1st, 2024. Since then, TRDA shares have decreased by 19.5% and is now trading at $12.15. View the best growth stocks for 2024 here .

When is Entrada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TRDA earnings forecast .

How were Entrada Therapeutics' earnings last quarter?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.22. The firm earned $41.85 million during the quarter, compared to analyst estimates of $27.82 million. Entrada Therapeutics had a negative trailing twelve-month return on equity of 2.89% and a negative net margin of 5.18%.

When did Entrada Therapeutics IPO?

Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share.

Who are Entrada Therapeutics' major shareholders?

Entrada Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley , Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher and Peter S Kim. View institutional ownership trends .

How do I buy shares of Entrada Therapeutics?

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TRDA

Entrada Therapeutics (TRDA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free TRDA Stock Alerts

$12.15

+0.24 (+2.02%)

(As of 04/19/2024 ET)

Compare

Today's Range: $11.81
▼
$12.19
50-Day Range: $11.58
▼
$15.17
52-Week Range: $10.62
▼
$18.44

Volume: 87,455 shs
Average Volume: 78,835 shs
Market Capitalization: $408.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get Entrada Therapeutics alerts:

Entrada Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 72.8% Upside
$21.00 Price Target
Short Interest: Bearish
9.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$119,272 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.54) to ($2.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.70 out of 5 stars

Medical Sector

629th out of 911 stocks

Pharmaceutical Preparations Industry

267th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Entrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Entrada Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.90% of the float of Entrada Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Entrada Therapeutics has a short interest ratio ("days to cover") of 23.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Entrada Therapeutics has recently decreased by 1.12%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Entrada Therapeutics does not currently pay a dividend.
Dividend Growth
Entrada Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRDA.

2.4

News and Social Media Coverage

News Sentiment
Entrada Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for TRDA on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Entrada Therapeutics insiders have bought 695.15% more of their company's stock than they have sold. Specifically, they have bought $119,272.00 in company stock and sold $15,000.00 in company stock.
Percentage Held by Insiders
Only 7.58% of the stock of Entrada Therapeutics is held by insiders.
Percentage Held by Institutions
86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.54) to ($2.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Entrada Therapeutics is -46.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Entrada Therapeutics is -46.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Entrada Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Entrada Therapeutics Stock (NASDAQ:TRDA)

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

TRDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRDA Stock News Headlines

April 11, 2024 | insidertrades.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,600 Shares

April 2, 2024 | insidertrades.com

Peter S. Kim Acquires 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 27, 2024 | insidertrades.com

Peter S. Kim Acquires 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

March 22, 2024 | insidertrades.com

Insider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 900 Shares of Stock

April 14, 2024 | nasdaq.com

Friday 4/12 Insider Buying Report: ATOS, TRDA

April 12, 2024 | americanbankingnews.com

Insider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Acquires 2,600 Shares of Stock

April 12, 2024 | insidermonkey.com

Insiders are Piling into These 5 Healthcare Stocks in 2024

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | msn.com

Insiders Buying America's Car-Mart And 2 Other Stocks

March 27, 2024 | finance.yahoo.com

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)

March 19, 2024 | finance.yahoo.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates

March 18, 2024 | markets.businessinsider.com

Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline

March 13, 2024 | markets.businessinsider.com

TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)

March 13, 2024 | finanznachrichten.de

Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024 | benzinga.com

Recap: Entrada Therapeutics Q4 Earnings

March 13, 2024 | globenewswire.com

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

February 23, 2024 | benzinga.com

Entrada Therapeutics Stock (NASDAQ:TRDA) Insider Trades

January 29, 2024 | finance.yahoo.com

‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks

January 8, 2024 | finance.yahoo.com

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

January 6, 2024 | msn.com

Oppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendation

January 3, 2024 | finance.yahoo.com

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

January 3, 2024 | finance.yahoo.com

Entrada Therapeutics Promotes Nathan J. Dowden to President

December 28, 2023 | finance.yahoo.com

Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares

December 20, 2023 | finance.yahoo.com

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

December 20, 2023 | finance.yahoo.com

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

December 11, 2023 | benzinga.com

Entrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and Dates

See More Headlines

Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TRDA
CUSIP: N/A
CIK: 1689375
Web: www.entradatx.com
Phone: 857-520-9158
Fax: N/A
Employees: 159
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $22.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +73.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,680,000.00
Net Margins: -5.18%
Pretax Margin: 9.34%
Return on Equity: -2.89%
Return on Assets: -1.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.33
Quick Ratio: 2.33

Sales & Book Value

Annual Sales: $129.01 million
Price / Sales: 3.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.26 per share
Price / Book: 1.67

Miscellaneous

Outstanding Shares: 33,600,000
Free Float: 31,054,000
Market Cap: $406.22 million
Optionable: Not Optionable
Beta: -0.50

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Dipal Doshi (Age 48)
CEO & Director
Comp: $902.08k
Mr. Nathan J. Dowden (Age 53)
President & COO
Comp: $654.6k
Dr. Natarajan Sethuraman Ph.D. (Age 62)
Chief Scientific Officer
Comp: $654.6k
Mr. Kory James Wentworth CPA (Age 44)
CFO & Treasurer
Dr. Jared Cohen J.D.
Ph.D., General Counsel
Ms. Kerry Robert M.S.
Senior Vice President of People
Ms. Karla MacDonald
Chief Corporate Affairs Officer
Mr. Kevin Healy Ph.D.
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TRDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Entrada Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRDA shares.
View TRDA analyst ratings or view top-rated stocks.
What is Entrada Therapeutics' stock price target for 2024?: 2 analysts have issued 12 month price targets for Entrada Therapeutics' stock. Their TRDA share price targets range from $20.00 to $22.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 72.8% from the stock's current price.
View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts.
How have TRDA shares performed in 2024?: Entrada Therapeutics' stock was trading at $15.09 on January 1st, 2024. Since then, TRDA shares have decreased by 19.5% and is now trading at $12.15.
View the best growth stocks for 2024 here.
When is Entrada Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TRDA earnings forecast.

How were Entrada Therapeutics' earnings last quarter?: Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.22. The firm earned $41.85 million during the quarter, compared to analyst estimates of $27.82 million. Entrada Therapeutics had a negative trailing twelve-month return on equity of 2.89% and a negative net margin of 5.18%.
When did Entrada Therapeutics IPO?: Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share.
Who are Entrada Therapeutics' major shareholders?: Entrada Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher and Peter S Kim.
View institutional ownership trends.
How do I buy shares of Entrada Therapeutics?: Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRDA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial